Related Experiment Videos
DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy
1Institute of Nuclear Medicine, University Hospital, School of Medicine, Basel, Switzerland.
European Journal of Nuclear Medicine
|July 1, 1997
Summary
This study shows DOTATOC, a peptide, successfully treated neuroendocrine tumors using yttrium-90. It also demonstrated potential as a diagnostic agent for neuroendocrine tumors.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmacology
Background:
- Neuroendocrine tumors (NETs) often express somatostatin receptors, making them targets for receptor-targeted therapies.
- Current diagnostic and therapeutic options for NETs require further optimization for efficacy and specificity.
Purpose of the Study:
- To evaluate the therapeutic efficacy of DOTATOC labeled with yttrium-90 (90Y-DOTATOC) in a patient with metastatic neuroendocrine carcinoma.
- To assess the diagnostic sensitivity of DOTATOC labeled with indium-111 (111In-DOTATOC) compared to OctreoScan in patients with neuroendocrine abdominal tumors.
Main Methods:
- Therapeutic application of 90Y-DOTATOC in one patient with somatostatin receptor-positive abdominal metastases.
- Diagnostic imaging using 111In-DOTATOC in three patients with histopathologically verified neuroendocrine abdominal tumors.
- Comparison of kidney-to-tumour uptake ratios between 111In-DOTATOC and OctreoScan.
Main Results:
- Successful tumor response and symptomatic relief were achieved in the patient treated with 90Y-DOTATOC.
- 111In-DOTATOC demonstrated diagnostic potential, although the kidney-to-tumour uptake ratio was lower than with OctreoScan.
Conclusions:
- DOTATOC, labeled with either 90Y for therapy or 111In for diagnostics, shows promise as a dual-purpose agent for neuroendocrine tumor management.
- Further investigation is warranted to optimize diagnostic performance and confirm therapeutic benefits of DOTATOC in neuroendocrine tumors.